03 maj: Edison CEO: Edf-A2A Deal Will "Certainly" Be Re..
03 maj: Oil Cos See US Limiting LNG Exports To Keep Low Gas Price
03-05-2012 13:02:00

Novatek Shares Pressured By Gas Tax, But Some See Future Benefits

By Alexander Kolyandr

Of DOW JONES NEWSWIRES

MOSCOW -(Dow Jones)- Shares in Novatek (NVTK.RS), Russia's largest independent natural gas producer, fell 4% early Thursday, extending losses to more than 12% in just two days on the back of the country's new tax regime for gas companies, but analysts are considering whether the tax rise will have benefits.

As President-elect Vladimir Putin seeks ways to fund a new wave of social spending promised during his election campaign without further straining the country's overstretched budget, Russia's government late Wednesday approved gradual mineral extraction tax rises for gas companies till 2015.

While the doubling of tax for state-controlled OAO Gazprom (GAZP.RS) had been broadly expected, and pushed the company's stock down only slightly, Novatek's tax rise is to be much faster and was generally unexpected. Novatek, which is paying lower extraction tax now, will face an almost four-times tax increase in three years, taking it to Gazprom's level.

Analysts estimate Novatek's earnings before interest, tax, depreciation and amortization, or Ebitda, will drop by between 10% and 20% in 2015 due to the tax rise. Brokerages lowered the company's target price and some of them cut recommendation on the stock.

"In the short term we expect Novatek's stock to continue to be under the pressure," said VTB Capital, which has a buy recommendation on the stock.

However, the leveling of taxes for Gazprom and independent producers may open up the lucrative export market to the latter.

"The question is highly political, but independents now have a very strong argument against Gazprom's export monopoly," UralSib bank notes.

The effect of the higher taxes may also be partly mitigated by a possible rise in domestic gas prices, which remain regulated by the government.

"The Russian government appears to be doing what it always does: penalizing the Russian consumer via higher gas prices and penalizing producers by raising taxes," Troika Dialog said.

Shares in Novatek bounced back Thursday and were up 0.4%, at RUB342.00, as of 1042 GMT.

-By Alexander Kolyandr, Dow Jones Newswires; +7 495 232-9192 alexander.kolyandr@dowjones.com

(END) Dow Jones Newswires

May 03, 2012 07:02 ET (11:02 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 sep
VWS
  Her er lidt at tænke over for en enhver Vestas aktionær!   Den 6. nov. 2012 var der valgdag i USA ..
40
17 sep
 
Jeg har lagt mærke til, at det er de samme personer, der igen og igen er negative til stort set alt...
23
14 sep
DLH
Den 105 år gamle historie om den tidligere storhandler af tropisk træ, Dalhoff, Larsen og Horneman, ..
23
20 sep
 
Ejer af fiskerestaurant i Sæby står til at miste 500.000 kr. ialt på retsag tabt mod Jensens Bøfhus!..
16
15 sep
FING-B
Så stop dog for pokker med alt det sædvanlige fnidder fnadder og forstå at dette debatforum stensikk..
14
18 sep
VELO
Jeg tog lige et genhør med svarene på dette spørgsmål i den telekonference, som Veloxis afholdt i fo..
13
14 sep
DLH
Udemærket opdatering på casen, Stockwatch. Et par kommentarer dog;   De laver et negativt EBIT på c..
13
17 sep
MAERSK-A
Jeg er enig med jer begge i det meste. Problemet er bare at mange forsøger at slå markedet ved at fi..
12
17 sep
DANSKE
6212?
12
17 sep
 
Jeg tror du tager fejl. 90 % af brugerne på EI ved i realiteten intet om økonomien i de selskaber de..
12

Maersk Line-chef tager på charmeoffensiv i Kina

19-09-2014 15:47:03
Den administrerende direktør for Maersk Line, Søren Skou, har besøgt de kinesiske myndigheder i et forsøg på at skaffe opbakning til en ny shipping-alliance med..

Novo/Sydbank: Novo sidder tungt på diabetes-tronen

19-09-2014 12:17:21
Sydbank fastholder sin anbefaling af Novo Nordisk-aktien til trods for, at den amerikanske lægemiddelstyrelse, FDA, torsdag aften har godkendt Novo-konkurrenten..

Novo: Nygodkendt diabetesmiddel giver lynhurtigt effekt

19-09-2014 11:31:02
Novo Nordisks nye kombinationspræparat til behandling af type 2 diabetes, Xultophy, yder allerede efter fire uger en betydelig blodsukkerkontrol.Det fremgår af ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. september 2014 06:04:51
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140919.1 - EUROWEB3 - 2014-09-21 06:04:51 - 2014-09-21 06:04:51 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x